![William R. Moore](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
William R. Moore
Profile
William R.
Moore held several positions in the pharmaceutical industry, including Chief Executive Officer at Vizuri Health Sciences LLC, President, Chief Executive Officer & Director at Innocrin Pharmaceuticals, Inc., Vice President-Target Discovery & Validation at Axys Pharmaceuticals, Inc., and Chief Scientific Officer at Viamet Pharmaceuticals, Inc. and Viamet Pharmaceuticals Corp.
Prior to his work in the pharmaceutical industry, he was a Senior Research Biochemist at Marion Merrell Dow, Inc. and an Assistant Professor in the Biochemistry Department at Cornell University.
Moore earned his doctorate degree from Brown University and his undergraduate degree from the University of Massachusetts.
Former positions of William R. Moore
Companies | Position | End |
---|---|---|
Vizuri Health Sciences LLC
![]() Vizuri Health Sciences LLC Pharmaceuticals: MajorHealth Technology Vizuri Health Sciences LLC engaged in the development of prescription and over-the-counter drug products. The company was headquartered in Wilmington, DE. | Chief Executive Officer | - |
Axys Pharmaceuticals, Inc.
![]() Axys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Axys Pharmaceuticals, Inc. engages in the development of integrated drugs. The company is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
Innocrin Pharmaceuticals, Inc.
![]() Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | Chief Executive Officer | 15/03/2017 |
Viamet Pharmaceuticals Corp.
![]() Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | Chief Tech/Sci/R&D Officer | - |
Viamet Pharmaceuticals, Inc.
![]() Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | Chief Tech/Sci/R&D Officer | - |
Training of William R. Moore
Brown University | Doctorate Degree |
University of Massachusetts | Undergraduate Degree |
Experiences
Positions held
Linked companies
Private companies | 7 |
---|---|
Locus Pharmaceuticals, Inc.
![]() Locus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Locus Pharmaceuticals is a pharmaceutical company focused on developing novel, small molecule therapeutics to address major unmet medical needs. Locus utilizes powerful and proprietary computational technologies running on Linux-based supercomputer clusters to simultaneously identify relevant binding sites on protein disease targets and rapidly generate novel, small molecules that bind specifically to those protein sites. In contrast to other computational approaches, the Locus technology requires only a high-resolution, 3-dimensional structure of the target protein to implement its drug discovery process. Locus Pharmaceuticals is synthesizing and testing novel drug candidates for the treatment of debilitating and life-threatening human diseases, including HIV/AIDS, cancer, arthritis and inflammation. | Health Technology |
Marion Merrell Dow, Inc. | Health Technology |
Viamet Pharmaceuticals, Inc.
![]() Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | Health Technology |
Viamet Pharmaceuticals Corp.
![]() Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | Health Technology |
Axys Pharmaceuticals, Inc.
![]() Axys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Axys Pharmaceuticals, Inc. engages in the development of integrated drugs. The company is headquartered in South San Francisco, CA. | Health Technology |
Innocrin Pharmaceuticals, Inc.
![]() Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | Health Technology |
Vizuri Health Sciences LLC
![]() Vizuri Health Sciences LLC Pharmaceuticals: MajorHealth Technology Vizuri Health Sciences LLC engaged in the development of prescription and over-the-counter drug products. The company was headquartered in Wilmington, DE. | Health Technology |
- Stock Market
- Insiders
- William R. Moore